Provided by Tiger Trade Technology Pte. Ltd.

ImmuCell

6.60
-0.0200-0.30%
Post-market: 6.600.00000.00%16:04 EST
Volume:5.42K
Turnover:35.77K
Market Cap:59.70M
PE:25.56
High:6.78
Open:6.56
Low:6.55
Close:6.62
52wk High:7.60
52wk Low:4.28
Shares:9.05M
Float Shares:6.02M
Volume Ratio:0.37
T/O Rate:0.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.2582
EPS(LYR):-0.2641
ROE:8.27%
ROA:3.79%
PB:2.00
PE(LYR):-24.99

Loading ...

ImmuCell kündigt Rückzug von zwei Vorstandsmitgliedern bis 2026 an

Reuters
·
Feb 10

ImmuCell Sets New Executive Pay Packages and Performance Incentives

Reuters
·
Feb 03

ImmuCell Corporation beschließt neue Vergütungsvereinbarungen für Führungskräfte

Reuters
·
Feb 03

ImmuCell Shares up 7.6% at $7.07 After the Bell Following Results

THOMSON REUTERS
·
Jan 09

ImmuCell Corp: Does Not Expect That Charges Will Result in Material Future Cash Expenditures - SEC Filing

THOMSON REUTERS
·
Jan 09

ImmuCell Corp: to Record About $3.6 Million in Non-Cash Impairment Write-Downs During Three-Month Period Ended Dec 31, 2025

THOMSON REUTERS
·
Jan 09

ImmuCell Q4 preliminary sales dip

Reuters
·
Jan 09

ImmuCell Reports 2025 Sales of $27.7 Million with Strong Tri-Shield Growth

Reuters
·
Jan 09

ImmuCell Corporation FY Product Sales USD 7.6 Million

THOMSON REUTERS
·
Jan 09

ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025

GlobeNewswire
·
Jan 09

ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus

GlobeNewswire
·
Jan 07

ImmuCell Puts Re-Tain On Pause After FDA Letter

Benzinga
·
Dec 26, 2025

ImmuCell Pauses Investment in Cow Mastitis Drug After Receiving FDA Incomplete Letter

Dow Jones
·
Dec 25, 2025

BRIEF-ImmuCell Pauses Investment In Re-Tain

Reuters
·
Dec 25, 2025

ImmuCell Corp - Expects $15.5 Mln Non-Cash Impairment Write-Down for Re-Tain During Q4

THOMSON REUTERS
·
Dec 25, 2025

ImmuCell Corp - Pauses Investment in Re-Tain

THOMSON REUTERS
·
Dec 25, 2025

ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®

GlobeNewswire
·
Dec 25, 2025

Fosun International Honored with TVB's Highest Accolade, "Outstanding ESG Award"

prnewswire
·
Dec 22, 2025

ImmuCell CEO Paul Francis Olivier te Boekhorst Acquires Common Shares

Reuters
·
Dec 04, 2025

Immucell Director Makes Bold Stock Purchase!

TIPRANKS
·
Nov 29, 2025